Health Care Down on Rotation Out of Sector - Health Care Roundup
Provided by
Dow Jones
Health-care companies ticked down as traders rotated into more rate-sensitive areas.
Eli Lilly will spend $5.3 billion to boost manufacturing capacity for its hot-selling anti-obesity drug Zepbound and affiliated diabetes drug Mounjaro, a huge investment to ease shortages of the popular drugs.
Novo Nordisk rose after the Danish obesity-drug giant said its Ozempic injection showed promise in a trial on patients with kidney conditions.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 24, 2024 17:25 ET (21:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase